ERα expressing tumors account for 70% of breast cancers [8] and carry a better prognosis than triple negative breast cancer (TNBC), classified as tumors that do not express ERα, PR and no amplification of HER2, which account for 15–20% of breast cancers [5, 9–12]. This evidence concerns the gene ERBB2 and breast carcinoma.